Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

NICK, We also raised 2.8 million in January.

"As of December 31, 2018, the Company had cash of $1.0 million, compared to $6.0 million at December 31, 2017. Net cash used in operating activities for the year ended December 31, 2018 was $6.1 million compared to $8.0 million for the comparable period in 2017. Net cash provided by financing activities for the year ended December 31, 2018 was $1.2 million."

18.5 million + 2.8 million + 1 million = 22.3 million less 1.5 million for first quarter burn = 20.8 million in cash now. At a 6.1 million burn 3+ years and at 8 million burn 2.5 years of expenses.

They should raise another 12 million minimum here to have 4 years of operating expense in cash.

The registration for Prexigerbersen, Venetoclax, decitabine combination trial will not occur until the 3rd quarter 2019 with interim results in mid 2020. A year and 3 months until "the next significant event" per PN. In the past BPTH has difficulty meeting their self-imposed guidelines.

"As a result of these updated data, Bio-Path(BPTH) now intends to enroll two registration-directed cohorts of the triple combination of prexigebersen + decitabine + venetoclax in untreated AML and high risk MDS patients, and refractory/relapsed AML and high risk MDS patients"

Simply put BPTH needs more cash and should raise it when the PPS is high , like now!